Clinical trials
Observational Insulin Resistance trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 7 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 8 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 85 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| John Sievenpiper | 5 |
| Assiut University | 4 |
| National Taiwan University Hospital | 3 |
| Sohag University | 3 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2 |
| Massachusetts General Hospital | 2 |
| National Institute for Medical Research, Tanzania | 2 |
| Shen Qu | 2 |
| Universita di Verona | 2 |
| University Hospital, Antwerp | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insulin Resistance | 85 |
| Obesity | 23 |
| Diabetes Mellitus | 20 |
| Metabolic Syndrome | 18 |
| Diabetes Mellitus, Type 2 | 16 |
| Overweight | 9 |
| Prediabetic State | 9 |
| Cardiovascular Diseases | 8 |
| Polycystic Ovary Syndrome | 8 |
| Hypertension | 7 |
Trials
Showing 1 to 25 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.